AZD6234
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese
AstraZeneca · Phase 1 · Completed · Enrollment 104
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Cohort 1 | n/r | n/r | n/r | n/r | n/r |
| Cohort 2 | n/r | n/r | n/r | n/r | n/r |
| Cohort 3 | n/r | n/r | n/r | n/r | n/r |
| Cohort 4 | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.